TP53 and Prognosis in mCRPC Survival: Biology or Coincidence?
Related Research units
Abstract
Cell-free circulating tumor DNA (ctDNA) or circulating tumor cell (CTC) assays are potentially powerful in the treatment of metastatic castration-resistant prostate cancer (mCRPC). A new study suggests that mutation of TP53 supersedes AR in predicting mCRPC survival. A role for TP53 mutation as a driver for mCRPC remains unexplored.See related article by De Laere et al., p. 1766.
Bibliographical data
| Original language | English |
|---|---|
| ISSN | 1078-0432 |
| DOIs | |
| Publication status | Published - 15.03.2019 |
| PubMed | 30610102 |
|---|
